S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
ORKA Inc. shares have reached a 52-week low, dipping to $10.15, marking a dramatic 63.44% decline over the past six months. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company’s financial health score remains weak at 1.52 out of 5. This latest price level reflects a notable downturn for the company, with the stock now trading 67% below its 52-week high of $31.13. The decline signals potential concerns among shareholders, particularly as analysts forecast a loss per share of $2.82 for fiscal year 2025. Despite current challenges, analyst price targets range from $20 to $49, suggesting potential upside from current levels. Investors are closely monitoring ORKA’s strategic responses to these challenges as they consider the stock’s long-term value and growth potential.
In other recent news, Oruka Therapeutics has announced an exclusive licensing agreement with Paragon Therapeutics, granting Oruka the worldwide rights to develop, manufacture, and commercialize antibodies targeting IL-17A/F and IL-23. This agreement could lead to up to $22 million in milestone payments to Paragon, with initial payments tied to the nomination of a development candidate and the first human dosing in a Phase 1 trial. Oruka will pay Paragon royalties on sales, which will decrease if there are no effective Paragon patents during the royalty term. Additionally, H.C. Wainwright has maintained a Buy rating and a $45 price target for Oruka, following the initiation of a Phase 1 study for its drug candidate, ORKA-001. The trial involves 24 healthy volunteers and aims to release interim data in the second half of 2025. If successful, Oruka plans a proof-of-concept study targeting psoriasis, with data expected in 2026. These developments highlight Oruka’s strategic moves to enhance its biopharmaceutical portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.